New ADHD Drug ALKS 7290 Shows Promise in Early Study
A Phase 1B study suggests the drug could help adults with ADHD, though larger trials are still needed to confirm its efficacy.
Updated on Oct. 21, 2026 in Substance Abuse
Live Poll
Would you prefer a non-stimulant medication to manage your ADHD symptoms if clinically proven effective?
An early-stage study shows the experimental drug ALKS 7290 may improve symptoms in adults with ADHD. The findings offer a potential new approach for adults looking for non-stimulant options as research moves toward larger trials.
Why it matters
Current ADHD treatments often rely on stimulant medications that can carry significant side effect profiles for many patients. This new drug aims to modulate brain pathways related to alertness and attention differently than existing therapies.
This Phase 1B randomized, double-blind, parallel-group trial tracked 50 adults with ADHD against 88 adults without the condition. Participants taking ALKS 7290 showed 14-point and 19-point median reductions in AISRS symptom scores at 20 mg and 50 mg doses, respectively, though long-term results are unknown.
The players
Washington University School of Medicine
A research institution affiliated with a consultant involved in the trial.
The details
ALKS 7290 works by binding to and activating orexin type 2 receptors in the brain to modulate pathways associated with vigilance, reward, and alertness. By targeting these specific pathways, the medication aims to decrease impulsivity and enhance focus. Reported side effects during the study included constipation, dizziness, insomnia, and changes in sustained attention.
Timeline
August 2026: The FDA approved the narcolepsy medication Orzeyful.
November 2026: Orzeyful is expected to be available for patient use.
2027: Researchers expect to release results from a Phase 2 trial of ALKS 7290.
Health Landscape
The development of ALKS 7290 reflects a broader push toward identifying non-stimulant alternatives for ADHD management. It builds on the ongoing research into orexin receptor modulation, a biological pathway recently validated by FDA approvals for narcolepsy treatments.
Adults currently managing ADHD symptoms may find this drug's mechanism of interest as a potential alternative to stimulants. If you are experiencing side effects from your current regimen, it is worth discussing the evolving landscape of non-stimulant research with your physician.
The takeaway
Early data suggest that targeting orexin receptors could offer a new way to manage ADHD symptoms in adults. Readers should continue to follow news on upcoming Phase 2 trial results and consult with their healthcare provider regarding any questions about their current medication plan.
What happens next
Results from a Phase 2 trial evaluating the efficacy of ALKS 7290 in adults with ADHD are expected in 2027.
Further reading
Learn more about evolving treatment options in the Substance Abuse section.
Source note: This article includes information reported by ADDitude.
Live Poll
Would you prefer a non-stimulant medication to manage your ADHD symptoms if clinically proven effective?
